mRNA Vaccine: How to Meet the Challenge of SARS-CoV-2

Yingqi Jin; Chen Hou; Yonghao Li; Kang Zheng; Chuan Wang

doi:10.3389/fimmu.2021.821538

mRNA Vaccine: How to Meet the Challenge of SARS-CoV-2

Front Immunol. 2022 Jan 21:12:821538. doi: 10.3389/fimmu.2021.821538. eCollection 2021.

Authors

Yingqi Jin¹, Chen Hou¹, Yonghao Li¹, Kang Zheng², Chuan Wang^{1

3}

Affiliations

¹ Institute of Pathogenic Biology, Hengyang Medical College, University of South China, Hengyang, China.
² Department of Clinical Laboratory, Hengyang Central Hospital, Hengyang, China.
³ Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, University of South China, Hengyang, China.

Abstract

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with high infectivity, pathogenicity, and variability, is a global pandemic that severely affected public health and the world economy. The development of safe and effective vaccines is crucial to the prevention and control of an epidemic. As an emerging technology, mRNA vaccine is widely used for infectious disease prevention and control and has significant safety, efficacy, and high production. It has received support and funding from many pharmaceutical enterprises and becomes one of the main technologies for preventing COVID-19. This review introduces the current status of SARS-CoV-2 vaccines, specifically mRNA vaccines, focusing on the challenges of developing mRNA vaccines against SARS-CoV-2, and discusses the relevant strategies.

Keywords: COVID-19; SARS-CoV-2; challenges; mRNA vaccine; strategies.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Animals
COVID-19 / immunology*
COVID-19 Vaccines / immunology*
Humans
SARS-CoV-2 / physiology*
Vaccine Development
Vaccine Efficacy
mRNA Vaccines / immunology*

Substances

COVID-19 Vaccines
mRNA Vaccines